Trial Profile
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jul 2022
Price :
$35
*
At a glance
- Drugs BNC 105 (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DisrupTOR-1
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 14 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.